Skip to main content
. Author manuscript; available in PMC: 2021 Oct 20.
Published in final edited form as: Semin Hematol. 2020 Oct 20;57(3):130–136. doi: 10.1053/j.seminhematol.2020.10.001

Table 2:

Most notable current pharmacogenomic interactions

Drug Most notable pharmacogenomic interactions Clinical implications; actionability
6-mercaptopurine TPMT, NUDT15 Increased myelosuppression; preemptive dose decrease indicated
Methotrexate SLCO1B1 Decreased clearance; avoidance of inhibitors during high-dose therapy
Asparaginase HLA DRB1*07:01, NFATC2 Increased risk of allergy; no intervention yet available
Vincristine CEP72 Increased neuropathy; prospective trial of preemptive dose decrease ongoing